In a report released on January 9, Jack Allen from Robert W. Baird maintained a Buy rating on Instil Bio (TIL – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $0.73.
According to TipRanks, Allen is an analyst with an average return of -15.2% and a 42.86% success rate. Allen covers the Healthcare sector, focusing on stocks such as Instil Bio, Lineage Therap, and Frequency Therapeutics.
Instil Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $14.34 and a one-year low of $0.47. Currently, Instil Bio has an average volume of 1.44M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
Read More on TIL:
- Instil Bio sees cash runway into 2025
- Instil Bio resumes clinical trial of ITIL-306 in lung, ovarian, renal cancer
- Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
- Instil Bio price target lowered to $5 from $14 at Baird
- Instil Bio discontinues ITIL-168 clinical programs
